Angiotensin IV does not exert prothrombotic effects in vivo
Qifang Wu1,2,3,4, Christine Gille1,2,3, Florian Maderspacher1,2,3
1Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.
Journal of Molecular and Cellular Cardiology Plus
|March 3, 2025
Summary
Angiotensin IV (AngIV) does not appear to promote blood clot formation. Studies found AngIV did not increase thrombosis or affect platelet aggregation, suggesting it does not regulate key prothrombotic mechanisms.
Area of Science:
- Cardiovascular Biology
- Hemostasis and Thrombosis
- Renal Physiology
Background:
- Thrombosis is a major cause of mortality linked to cardiovascular diseases.
- Dysregulation of the renin-angiotensin system contributes to thrombotic events.
- Angiotensin II (AngII) promotes platelet aggregation, but the role of other angiotensins, like Angiotensin IV (AngIV), in thrombus formation is unclear.
Purpose of the Study:
- To investigate the potential prothrombotic effects of Angiotensin IV (AngIV).
- To explore AngIV-mediated mechanisms in thrombus formation.
Main Methods:
- Continuous administration of AngIV to mice for 4 weeks using osmotic minipumps.
- Assessment of thrombus formation, platelet counts, and platelet aggregation.
- Measurement of heart HGF, c-MET, or PAI-1 expression levels.
- In vitro testing of human platelet aggregation with HGF.
Main Results:
- AngIV treatment did not induce thrombus formation in the heart.
- Platelet numbers and aggregation were not affected by AngIV.
- No alterations in HGF, c-MET, or PAI-1 expression were observed in the heart.
- Human platelet aggregation remained unchanged when incubated with HGF.
Conclusions:
- Angiotensin IV (AngIV) does not exhibit prothrombotic effects in mice.
- AngIV does not appear to regulate key mechanisms involved in thrombus formation, including platelet aggregation and specific gene expression.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:25Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
447
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
447
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
568
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
123
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
123
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
753
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
753